{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:52:57Z","timestamp":1793321577880,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"51","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.vaccine.2021.10.083","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T01:54:03Z","timestamp":1636595643000},"page":"7379-7386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Production and purification of an active CRM197 in Pichia pastoris and its immunological characterization using a Vi-typhoid antigen vaccine"],"prefix":"10.1016","volume":"39","author":[{"given":"Rochelle","family":"Aw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muktadir R.","family":"Ashik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariful A.Z.M.","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Mainuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Ashraful","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad M.","family":"Ahasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Polizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2021.10.083_b0005","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.vaccine.2010.11.022","article-title":"Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi","volume":"29","author":"Micoli","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2021.10.083_b0010","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.xphs.2018.03.002","article-title":"Analytical Comparability Assessments of 5 Recombinant CRM197 Proteins From Different Manufacturers and Expression Systems","volume":"107","author":"Hickey","year":"2018","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.vaccine.2021.10.083_b0015","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1016\/S0021-9258(19)43810-6","article-title":"Diphtheria toxin and related proteins. I. Isolation and properties of mutant proteins serologically related to diphtheria toxin","volume":"248","author":"Uchida","year":"1973","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.vaccine.2021.10.083_b0020","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jbiotec.2011.08.024","article-title":"Overexpression and purification of the recombinant diphtheria toxin variant CRM197 in Escherichia coli","volume":"156","author":"Stefan","year":"2011","journal-title":"J Biotechnol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.083_b0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev.micro.62.081307.162848","article-title":"Molecular mechanisms of the cytotoxicity of ADP-ribosylating toxins","volume":"62","author":"Deng","year":"2008","journal-title":"Annu Rev Microbiol"},{"issue":"27","key":"10.1016\/j.vaccine.2021.10.083_b0030","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1016\/j.vaccine.2010.04.072","article-title":"Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use","volume":"28","author":"Shinefield","year":"2010","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2021.10.083_b0035","doi-asserted-by":"crossref","first-page":"e25398","DOI":"10.1371\/journal.pone.0025398","article-title":"Safety, immunogenicity and dose ranging of a new Vi-CRM(1)(9)(7) conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults","volume":"6","author":"van Damme","year":"2011","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.vaccine.2021.10.083_b0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1473-3099(13)70241-X","article-title":"Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials","volume":"14","author":"Bhutta","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"39","key":"10.1016\/j.vaccine.2021.10.083_b0045","doi-asserted-by":"crossref","first-page":"24443","DOI":"10.1073\/pnas.2005857117","article-title":"Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM197 conjugate vaccine","volume":"117","author":"Micoli","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.vaccine.2021.10.083_b0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.biologicals.2011.05.004","article-title":"Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications","volume":"39","author":"Broker","year":"2011","journal-title":"Biologicals"},{"issue":"3","key":"10.1016\/j.vaccine.2021.10.083_b0055","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1128\/aem.46.3.560-564.1983","article-title":"Isolation and characterization of Corynebacterium diphtheriae nontandem double lysogens hyperproducing CRM197","volume":"46","author":"Rappuoli","year":"1983","journal-title":"Appl Environ Microbiol"},{"issue":"7","key":"10.1016\/j.vaccine.2021.10.083_b0060","doi-asserted-by":"crossref","first-page":"1700168","DOI":"10.1002\/biot.201700168","article-title":"High-yield production of recombinant CRM197, a non-toxic mutant of diphtheria toxin, in the periplasm of Escherichia coli","volume":"12","author":"Goffin","year":"2017","journal-title":"Biotechnol J"},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.083_b0065","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jb\/mvm115","article-title":"Transgenic mice expressing a fully nontoxic diphtheria toxin mutant, not CRM197 mutant, acquire immune tolerance against diphtheria toxin","volume":"142","author":"Kimura","year":"2007","journal-title":"J Biochem"},{"issue":"5","key":"10.1016\/j.vaccine.2021.10.083_b0070","first-page":"588","article-title":"Saccharomyces cerevisiae spheroplasts are sensitive to the action of diphtheria toxin","volume":"2","author":"Murakami","year":"1982","journal-title":"Mol Cell Biol"},{"issue":"4-5","key":"10.1016\/j.vaccine.2021.10.083_b0075","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12033-017-0001-3","article-title":"Molecular Cloning, Structural Modeling and the Production of Soluble Triple-Mutated Diphtheria Toxoid (K51E\/G52E\/E148K) Co-expressed with Molecular Chaperones in Recombinant Escherichia coli","volume":"59","author":"Uthailak","year":"2017","journal-title":"Mol Biotechnol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.10.083_b0080","first-page":"253","article-title":"Secretory expression of recombinant diphtheria toxin mutants in B. subtilis","volume":"19","author":"Zhou","year":"1999","journal-title":"J Tongji Med Univ"},{"key":"10.1016\/j.vaccine.2021.10.083_b0085","unstructured":"Retallack DM CL, inventor High level expression of recombinant toxin proteins patent US 896636 B22014."},{"issue":"12","key":"10.1016\/j.vaccine.2021.10.083_b0090","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1007\/s00253-014-5732-5","article-title":"Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production","volume":"98","author":"Ahmad","year":"2014","journal-title":"Appl Microbiol Biotechnol"},{"issue":"2","key":"10.1016\/j.vaccine.2021.10.083_b0095","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1046-5928(02)00009-8","article-title":"Gene optimization is necessary to express a bivalent anti-human anti-T cell immunotoxin in Pichia pastoris","volume":"25","author":"Woo","year":"2002","journal-title":"Protein Expr Purif"},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.083_b0100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jbiotec.2005.07.004","article-title":"Minimization of aggregation of secreted bivalent anti-human T cell immunotoxin in Pichia pastoris bioreactor culture by optimizing culture conditions for protein secretion","volume":"121","author":"Woo","year":"2006","journal-title":"J Biotechnol"},{"issue":"2","key":"10.1016\/j.vaccine.2021.10.083_b0105","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1046-5928(03)00129-3","article-title":"Targeted introduction of a diphtheria toxin resistant mutation into the chromosomal EF-2 locus of Pichia pastoris and expression of immunotoxin in the EF-2 mutants","volume":"30","author":"Liu","year":"2003","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.vaccine.2021.10.083_b0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jim.2013.09.006","article-title":"Development of a diphtheria toxin-based recombinant porcine IL-2 fusion toxin for depleting porcine CD25+ cells","volume":"398-399","author":"Peraino","year":"2013","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2021.10.083_b0115","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jim.2017.05.008","article-title":"Ontak-like human IL-2 fusion toxin","volume":"448","author":"Wang","year":"2017","journal-title":"J Immunol Methods"},{"issue":"7","key":"10.1016\/j.vaccine.2021.10.083_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201060","article-title":"Efficient recovery of recombinant CRM197 expressed as inclusion bodies in E. coli","volume":"13","author":"Park","year":"2018","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.083_b0125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2144\/05381BM04","article-title":"Condensed protocol for competent cell preparation and transformation of the methylotrophic yeast Pichia pastoris","volume":"38","author":"Lin-Cereghino","year":"2005","journal-title":"Biotechniques"},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.083_b0130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12934-016-0432-8","article-title":"Liquid PTVA: a faster and cheaper alternative for generating multi-copy clones in Pichia pastoris","volume":"15","author":"Aw","year":"2016","journal-title":"Microb Cell Fact"},{"issue":"42","key":"10.1016\/j.vaccine.2021.10.083_b0135","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1016\/j.vaccine.2013.08.037","article-title":"A novel method for purification of Vi capsular polysaccharide produced by Salmonella enterica subspecies enterica serovar Typhi","volume":"31","author":"Kothari","year":"2013","journal-title":"Vaccine"},{"issue":"44","key":"10.1016\/j.vaccine.2021.10.083_b0140","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.1016\/j.vaccine.2011.08.019","article-title":"Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity","volume":"29","author":"An","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2021.10.083_b0145","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.gene.2013.01.062","article-title":"The effect of alpha-mating factor secretion signal mutations on recombinant protein expression in Pichia pastoris","volume":"519","author":"Lin-Cereghino","year":"2013","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.083_b0150","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1046-5928(03)00136-0","article-title":"Production of the active antifungal Pisum sativum defensin 1 (Psd1) in Pichia pastoris: overcoming the inefficiency of the STE13 protease","volume":"31","author":"Cabral","year":"2003","journal-title":"Protein Expr Purif"},{"issue":"9","key":"10.1016\/j.vaccine.2021.10.083_b0155","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.procbio.2009.04.019","article-title":"Lowering induction temperature for enhanced production of polygalacturonate lyase in recombinant Pichia pastoris","volume":"44","author":"Wang","year":"2009","journal-title":"Process Biochem"},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.083_b0160","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1475-2859-2-6","article-title":"Temperature limited fed-batch technique for control of proteolysis in Pichia pastoris bioreactor cultures","volume":"2","author":"Jahic","year":"2003","journal-title":"Microb Cell Fact"},{"issue":"2","key":"10.1016\/j.vaccine.2021.10.083_b0165","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nrmicro1087","article-title":"The humanization of N-glycosylation pathways in yeast","volume":"3","author":"Wildt","year":"2005","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.083_b0170","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1475-2859-12-128","article-title":"Can too many copies spoil the broth?","volume":"12","author":"Aw","year":"2013","journal-title":"Microb Cell Fact"},{"issue":"4","key":"10.1016\/j.vaccine.2021.10.083_b0175","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/bit.10904","article-title":"Effects of gene dosage, promoters, and substrates on unfolded protein stress of recombinant Pichia pastoris","volume":"85","author":"Hohenblum","year":"2004","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2021.10.083_b0180","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180238","article-title":"Structural and immunological characterization of E. coli derived recombinant CRM197 protein used as carrier in conjugate vaccines","volume":"38","author":"Mishra","year":"2018","journal-title":"Biosci Rep"},{"issue":"6","key":"10.1016\/j.vaccine.2021.10.083_b0185","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1128\/AEM.70.6.3370-3376.2004","article-title":"Increasing secretion of a bivalent anti-T-cell immunotoxin by Pichia pastoris","volume":"70","author":"Woo","year":"2004","journal-title":"Appl Environ Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.083_b0190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/bit.26440","article-title":"Development of a general defined medium for Pichia pastoris","volume":"115","author":"Matthews","year":"2018","journal-title":"Biotechnol Bioeng"},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.083_b0195","doi-asserted-by":"crossref","DOI":"10.1038\/srep20488","article-title":"Cross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sites","volume":"6","author":"M\u00f6ginger","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2021.10.083_b0200","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0167-7012(01)00290-1","article-title":"Novel vaccine strategies to T-independent antigens","volume":"47","author":"Lesinski","year":"2001","journal-title":"J Microbiol Methods"},{"issue":"43","key":"10.1016\/j.vaccine.2021.10.083_b0205","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1016\/j.vaccine.2012.05.081","article-title":"Immunization with the conjugate vaccine Vi-CRM197 against Salmonella Typhi induces Vi-specific mucosal and systemic immune responses in mice","volume":"30","author":"Fiorino","year":"2012","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21014328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21014328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:04:57Z","timestamp":1759403097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21014328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":41,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0264410X21014328"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.10.083","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Production and purification of an active CRM197 in Pichia pastoris and its immunological characterization using a Vi-typhoid antigen vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.10.083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}